Springhood Child Health Ventures

The firm addresses the persistent underinvestment in pediatric drug and device development. The majority of pharmaceutical R&D targets adult populations because of larger addressable markets and well-established regulatory pathways. Pediatric trials are more difficult to enroll, endpoints are less standardized, and commercial returns are often smaller absent regulatory incentives. Springhood funds companies that accept this complexity in exchange for the moats created by orphan-drug exclusivities, FDA priority review vouchers, and deeply unmet clinical needs.

Companies developing therapies for rare pediatric diseases can qualify for FDA Priority Review Vouchers upon drug approval, which have sold for over $100 million and can materially de-risk a venture investment. Additional incentives include extended market exclusivity periods under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. Medical device companies pursuing humanitarian device exemptions for pediatric indications also benefit from streamlined regulatory pathways and lower clinical-trial size requirements.